Navigation Links
Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
Date:11/2/2007

MONTVALE, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that it will report its third quarter financial results on Thursday, November 8, 2007, before the U.S. financial markets open. Management will provide a Company update and discuss the third quarter results during a conference call on Thursday, November 8, 2007, at 9:00 a.m. ET.

Investors and other interested parties may access the call as follows:

Date: Thursday, November 8, 2007

Time: 9:00 a.m. ET

Telephone (U.S.): 866.314.9013

Telephone (international): 617.213.8053

Participant Passcode: 64962595

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. ET on Thursday, November 8, 2007, until Thursday, November 15, 2007. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 43832722. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Engineers visualize electric memory as it fades
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle, WARF announce partnership to lure stem cell companies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):